DeepMed Research

Suvorexant

Generic Name: Suvorexant

Brand Names: Belsomra

Drug Type: Small Molecule

Chemical Formula: C_₂₃H_₂₃ClN_₆O_₂

CAS Number: 1030377-33-3

Unique Ingredient Identifier: 081L192FO9

Background: Suvorexant is a selective dual antagonist of orexin receptors OX1R and OX2R that promotes sleep by reducing wakefulness and arousal. It has been approved for the treatment of insomnia.

Indication: Suvorexant is indicated for the treatment of insomnia characterized by difficulties with sleep onset and/or sleep maintenance.

Associated Conditions: Insomnia

Clinical Trials

Orexin Antagonism for Suicide Risk: a Proof-of-Concept Clinical Trial

Phase 2

Not yet recruiting

Conditions: Suicide Risk
Major Depressive Disorder (MDD)

Interventions: Drug: Suvorexant (dual orexin receptor antagonist)

First Posted Date: 2025-03-03

Last Posted Date: 2025-03-03

Lead Sponsor: Marianne Goodman

Target Recruit Count: 30

Registration Number: NCT06854224

Locations: 🇺🇸
James J. Peters Veterans Affairs Medical Center, Bronx, New York, United States

Suvorexant for Insomnia to Prevent Delirium in Hospitalized Cancer Patients

Phase 4

Withdrawn

Conditions: Advanced Malignant Solid Neoplasm
Delirium
Hematopoietic and Lymphatic System Neoplasm
Insomnia

Interventions: Other: Best Practice
Other: Electronic Health Record Review
Other: Interview
Other: Questionnaire Administration
Drug: Suvorexant

First Posted Date: 2025-02-19

Last Posted Date: 2025-05-01

Lead Sponsor: Mayo Clinic

Target Recruit Count: 14

Registration Number: NCT06834386

Locations: 🇺🇸
Mayo Clinic in Rochester, Rochester, Minnesota, United States

The Effects of Orexin Antagonism on Fear Extinction in PTSD

Phase 4

Not yet recruiting

Conditions: Insomnia
PTSD

Interventions: Drug: Suvorexant
Drug: Placebo

First Posted Date: 2025-01-23

Last Posted Date: 2025-01-30

Lead Sponsor: VA Office of Research and Development

Target Recruit Count: 40120

Registration Number: NCT06788522

Locations: 🇺🇸
San Francisco VA Medical Center, San Francisco, CA, San Francisco, California, United States
🇺🇸
Ralph H. Johnson VA Medical Center, Charleston, SC, Charleston, South Carolina, United States

Suvorexant for Treatment of AUD and PTSD

Phase 2

Not yet recruiting

Conditions: Alcohol Use Disorder (AUD)
Post Traumatic Stress Disorder (PTSD)
Insomnia

Interventions: Other: Placebo
Drug: Suvorexant

First Posted Date: 2024-11-07

Last Posted Date: 2024-11-12

Lead Sponsor: Pharmacotherapies for Alcohol and Substance Use Disorders Alliance

Target Recruit Count: 76

Registration Number: NCT06679062

Locations: 🇺🇸
University of California - Los Angeles, Los Angeles, California, United States
🇺🇸
The University of Texas Health Science Center - Houston, Houston, Texas, United States

A Study of Suvorexant (MK-4305) for the Treatment of Insomnia in Participants With Opioid Use Disorder (MK-4305-098)

Phase 3

Not yet recruiting

Conditions: Insomnia

Interventions: Drug: Suvorexant
Drug: Placebo

First Posted Date: 2024-10-24

Last Posted Date: 2025-01-31

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 300

Registration Number: NCT06655883

Evaluation of Suvorexant for Reduction of Brain Reactivity in Patients With Cannabis Use Disorder (Pilot Study)

Phase 4

Recruiting

Conditions: Cue-reactivity
Cannabis Use Disorder
Functional MRI
Orexin Antagonist

Interventions: Drug: Suvorexant

First Posted Date: 2024-09-05

Last Posted Date: 2025-05-18

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 10

Registration Number: NCT06584942

Locations: 🇺🇸
Center for Addiction Medicine, Massachusetts General Hospital, Boston, Massachusetts, United States

Suvorexant for Alcohol Use Disorder (AUD): Neural Mechanisms

Phase 1

Recruiting

Conditions: Normal Physiology
Alcohol Use Disorder (AUD)

Interventions: Drug: Suvorexant
Drug: Placebo

First Posted Date: 2024-07-03

Last Posted Date: 2025-05-20

Lead Sponsor: National Institute on Alcohol Abuse and Alcoholism (NIAAA)

Target Recruit Count: 150

Registration Number: NCT06484075

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Suvorexant and Alcohol

Early Phase 1

Recruiting

Conditions: Alcohol Use Disorder

Interventions: Drug: Alcohol
Drug: Suvorexant
Drug: Placebo

First Posted Date: 2024-03-22

Last Posted Date: 2024-12-12

Lead Sponsor: University of Kentucky

Target Recruit Count: 30

Registration Number: NCT06326684

Locations: 🇺🇸
Psychopharmacology of Addiction Laboratory, Lexington, Kentucky, United States

Double-blind Randomized Controlled Trial Comparing Suvorexant 20 mg to Placebo for Treatment of Insomnia in Cancer Survivors

Phase 4

Not yet recruiting

Conditions: Breast Cancer
Insomnia

Interventions: Drug: Suvorexant Tablets
Other: Placebo Control

First Posted Date: 2023-12-08

Last Posted Date: 2024-08-01

Lead Sponsor: Medical University of South Carolina

Target Recruit Count: 44

Registration Number: NCT06162663

Locations: 🇺🇸
MUSC Department of Family Medicine, Charleston, South Carolina, United States

Insomnia Treatment and EMA (Ecological Momentary Assessment) Outcomes

Phase 2

Recruiting

Conditions: Insomnia

Interventions: Behavioral: Baseline surveys, Cognitive testing and EMAs
Device: Actiwatch
Drug: suvorexant (or placebo)
Other: Placebo

First Posted Date: 2023-06-18

Last Posted Date: 2023-11-14

Lead Sponsor: University of Maryland, Baltimore

Target Recruit Count: 50

Registration Number: NCT05908526

Locations: 🇺🇸
University of Maryland, Baltimore, Baltimore, Maryland, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy